Prana Biotechnology Ltd (PBT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Prana Biotechnology Ltd (PBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013607
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prana Biotechnology Ltd (Prana Biotech) is a pharmaceutical company that develops therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer’s disease, brain cancer, and other major age-related degenerative disorders. It is developing first-in-class therapies for the treatment of neurodegenerative disease. Prana Biotech develops technology platform in association with various institutions and medical institutes. The company also maintains a library of metal protein attenuating compounds that may support new therapies for neurodegenerative disease. It also conducts various clinical programs. The company collaborates with various universities for its research projects. Prana Biotech is headquartered in Melbourne, Victoria, Australia.

Prana Biotechnology Ltd (PBT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Prana Biotech Enters into Research Agreement with Takeda Pharma 10
Equity Offering 11
Prana Biotech Plans to Raise upto USD50 Million in Public Offering of Securities 11
Prana Biotech Completes Second Tranche Of Private Placement Of Shares For US$6 Million 12
Prana Biotechnology Announces Public Offering Of American Depositary Receipts For US$47.2 Million 13
Prana Biotech Completes Rights Offering Of Shares For US$2.1 Million 14
Prana Biotech Raises USD7.3 Million in Private Placement of Shares 15
Prana Biotech Completes Private Placement Of Shares For US$6 Million 16
Prana Biotech Completes Private Placement Of Shares For US$0.4 Million 17
Prana Biotech Completes Private Placement Of Shares For US$0.2 Million 18
Prana Biotech Completes Private Placement Of Ordinary Shares For US$1.3 Million 19
Prana Biotech Completes Private Placement Of US$1 Million 20
Prana Biotech Completes Private Placement Of US$6.19 Million 21
Prana Biotechnology Ltd – Key Competitors 22
Prana Biotechnology Ltd – Key Employees 23
Prana Biotechnology Ltd – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Corporate Communications 25
Jun 05, 2017: Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development 25
Apr 11, 2016: Prana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission 26
Other Significant Developments 27
Dec 23, 2016: Prana Business Update 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Prana Biotechnology Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Prana Biotechnology Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Prana Biotech Enters into Research Agreement with Takeda Pharma 10
Prana Biotech Plans to Raise upto USD50 Million in Public Offering of Securities 11
Prana Biotech Completes Second Tranche Of Private Placement Of Shares For US$6 Million 12
Prana Biotechnology Announces Public Offering Of American Depositary Receipts For US$47.2 Million 13
Prana Biotech Completes Rights Offering Of Shares For US$2.1 Million 14
Prana Biotech Raises USD7.3 Million in Private Placement of Shares 15
Prana Biotech Completes Private Placement Of Shares For US$6 Million 16
Prana Biotech Completes Private Placement Of Shares For US$0.4 Million 17
Prana Biotech Completes Private Placement Of Shares For US$0.2 Million 18
Prana Biotech Completes Private Placement Of Ordinary Shares For US$1.3 Million 19
Prana Biotech Completes Private Placement Of US$1 Million 20
Prana Biotech Completes Private Placement Of US$6.19 Million 21
Prana Biotechnology Ltd, Key Competitors 22
Prana Biotechnology Ltd, Key Employees 23

★海外企業調査レポート[Prana Biotechnology Ltd (PBT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Channel Four Telivision Corp:企業の戦略的SWOT分析
    Channel Four Telivision Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Minnetronix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Minnetronix Inc (Minnetronix) is a medical device company that offers medical system integrators. The company designs electronic and electromechanical systems. It offers products such as intraperitoneal heating and fluids control, brain stimulation system, 3-D imaging for ear canal measureme …
  • Canada Post Corporation:企業の戦略・SWOT・財務分析
    Canada Post Corporation - Strategy, SWOT and Corporate Finance Report Summary Canada Post Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Novartis Pharmaceuticals Corp:企業のM&A・事業提携・投資動向
    Novartis Pharmaceuticals Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Novartis Pharmaceuticals Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Hikma Pharmaceuticals Plc (HIK):企業の財務・戦略的SWOT分析
    Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • SGS SA (SGSN):企業の財務・戦略的SWOT分析
    SGS SA (SGSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • John Menzies Plc:企業の戦略・SWOT・財務分析
    John Menzies Plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Monsanto Co (MON):企業の財務・戦略的SWOT分析
    Monsanto Co (MON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Panacea Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Panacea Pharmaceuticals Inc (Panacea) is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutic and diagnostic products for the treatment of cancer and central nervous system diseases. The company’s pipeline products include PAN-301-1, a human aspa …
  • Instrumentation Laboratory Company:企業の製品パイプライン分析2018
    Summary Instrumentation Laboratory Company (IL), a subsidiary of Werfen Life Group, is a medical device company with focus on in vitro diagnostics (IVD) devices. The company develops, manufactures, and distributes IVD instruments, related reagents and controls for hospitals and clinical laboratories …
  • ISS AS:企業のM&A・事業提携・投資動向
    ISS AS - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ISS AS Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Nigerian Breweries Plc:企業の戦略・SWOT・財務情報
    Nigerian Breweries Plc - Strategy, SWOT and Corporate Finance Report Summary Nigerian Breweries Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CSE Global Ltd (544):石油・ガス:M&Aディール及び事業提携情報
    Summary CSE Global Limited (CSE) is a technology company offering process control systems and integrated plant communication systems. It’s process control systems offers emergency shutdown systems, process shutdown systems, integrated control & safety systems and fire and gas detection systems, well …
  • Huadian Power International Corporation Ltd (1071):企業の財務・戦略的SWOT分析
    Huadian Power International Corporation Ltd (1071) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Vascular Biogenics Ltd (VBLT):企業の財務・戦略的SWOT分析
    Summary Vascular Biogenics Ltd (VBL Therapeutics) is a biopharmaceutical company. It discovers, develops and commercializes gene-therapy medicines for the treatment of cancer and inflammatory diseases. The company’s lead product candidate VB-111, a gene-based biologic agent is developed to treat rec …
  • Steel Connect Inc (STCN):企業の財務・戦略的SWOT分析
    Steel Connect Inc (STCN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Linn Energy Inc (LNGG):石油・ガス:M&Aディール及び事業提携情報
    Summary Linn Energy Inc (Linn Energy), formerly Linn Energy LLC, is an independent energy company. It explores for, develops, and produces oil, natural gas, and natural gas liquids (NGLs). The company has upstream assets in various operating regions in the US such as Hugoton Basin, the Mid-Continent …
  • RSWM Ltd. (RSWM):企業の財務・戦略的SWOT分析
    RSWM Ltd. (RSWM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone produ …
  • Collplant Biotechnologies Ltd (CLGN):企業の製品パイプライン分析
    Summary Collplant Biotechnologies Ltd (CollPlant) is a regenerative medicine company that carries out the development and commercialization of tissue repair products. The company offers orthobiologics, wound care, and pipeline products. Its orthobiologics products include VergenixSTR and VergenixBVF …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆